Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
QDENGA® (TAK-003) is a dengue vaccine that is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four dengue virus serotypes and is designed to protect against any of these serotypes.
Lead Product(s): Dengue Tetravalent Vaccine,9vHPV Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Qdenga
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
Data include exploratory analysis showing Livtencity treated patients with post-transplant cytomegalovirus infections/disease had reductions in hospitalizations (34.8%) and length of hospital stay (53.8%) compared to those treated with conventional antiviral therapies.
Lead Product(s): Maribavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Livtencity
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2022
Details:
The approval of Nuvaxovid COVID-19 Vaccine, is based on Takeda’s New Drug Application submission which included interim results from the Phase 1/2 study in Japan that were positive and consistent with previously reported clinical trial results.
Lead Product(s): NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuvaxovid
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Novavax
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
Actemra (tocilizumab), IL-6 inhibitor, approval is based on the results of RECOVERY phase III studies in hospitalized patients with COVID-19 for the treatment of SARS-CoV-2 pneumonia.
Lead Product(s): Tocilizumab
Therapeutic Area: Infections and Infectious Diseases Product Name: Actemra
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2022
Details:
LIVTENCITY (maribavir), an orally bioavailable anti-CMV compound, is the first and only antiviral agent that targets and inhibits the pUL97 protein kinase and its natural substrates.
Lead Product(s): Maribavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Livtencity
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2021
Details:
This application is based on the results from the global phase III clinical study (REGN-COV 2067 study) in patients with COVID-19 and a phase I clinical study to examine the safety, tolerability, and pharmacokinetics in Japanese.
Lead Product(s): Casirivimab,Imdevimab
Therapeutic Area: Infections and Infectious Diseases Product Name: REGEN-COV
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2021
Details:
This interim analysis showed that binding antibody and neutralizing antibody titers were elevated at 28 days after the second dose in 100% of people vaccinated with two 0.5ml doses of TAK-919 given 28 days apart.
Lead Product(s): TAK-919
Therapeutic Area: Infections and Infectious Diseases Product Name: TAK-919
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2021
Details:
Daiichi Sankyo will terminate its marketing alliance agreement for the Squarekids® subcutaneous injection syringe, a tetravalent combination vaccine and its joint development agreement on pentavalent combination vaccine with Sanofi K.K.
Lead Product(s): Bordetella pertussis protective antigen,Diphtheria toxoid,Tetanus toxoid
Therapeutic Area: Infections and Infectious Diseases Product Name: Squarekids
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination March 31, 2021
Details:
The manufacture of the COVID-19 vaccine, AZD1222, will be undertaken by Daiichi Sankyo Biotech Company, at a facility dedicated to the Ministry of Health, Labour and Welfare’s “project to establish a system for developing and producing novel influenza virus vaccines.
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 05, 2021
Details:
The phase 3 study enrolled 103 patients and is assessing the safety and efficacy of isavuconazole in adult Japanese patients suffering from deep-seated mycoses, including invasive aspergillosis and mucormycosis.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Basilea Pharmaceutica
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
